These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36113085)

  • 21. Eltrombopag: A Review in Paediatric Chronic Immune Thrombocytopenia.
    Burness CB; Keating GM; Garnock-Jones KP
    Drugs; 2016 May; 76(8):869-78. PubMed ID: 27151255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia.
    Bussel JB; Kuter DJ; Aledort LM; Kessler CM; Cuker A; Pendergrass KB; Tang S; McIntosh J
    Blood; 2014 Jun; 123(25):3887-94. PubMed ID: 24802775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Incidence of Treatment-Related Adverse Events of Thrombopoietin Receptor Agonists in Adults with Immune Thrombocytopenia: A Systematic Review and Network Meta-Analysis of Randomized Controlled Study.
    Liu Y; Zhang HX; Su J; Geng QC; Lin X; Feng CX
    Acta Haematol; 2023; 146(3):173-184. PubMed ID: 36572014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of Avatrombopag in Patients with Chronic Immune Thrombocytopenia: A Systematic Literature Review and Network Meta-Analysis.
    Wojciechowski P; Wilson K; Nazir J; Pustułka I; Tytuła A; Smela B; Pochopien M; Vredenburg M; McCrae KR; Jurczak W
    Adv Ther; 2021 Jun; 38(6):3113-3128. PubMed ID: 33934279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States.
    Tremblay G; Dolph M; Roy AN; Said Q; Forsythe A
    Clin Ther; 2020 May; 42(5):860-872.e8. PubMed ID: 32199608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure.
    Terrault NA; Hassanein T; Howell CD; Joshi S; Lake J; Sher L; Vargas H; McIntosh J; Tang S; Jenkins TM
    J Hepatol; 2014 Dec; 61(6):1253-9. PubMed ID: 25048952
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.
    Cheng G; Saleh MN; Marcher C; Vasey S; Mayer B; Aivado M; Arning M; Stone NL; Bussel JB
    Lancet; 2011 Jan; 377(9763):393-402. PubMed ID: 20739054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag.
    Kuter DJ
    Blood Rev; 2022 May; 53():100909. PubMed ID: 34815110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eltrombopag: a novel oral thrombopoietin receptor agonist.
    Corman SL; Mohammad RA
    Ann Pharmacother; 2010 Jun; 44(6):1072-9. PubMed ID: 20460556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
    Dodillet H; Kreuzer KA; Monsef I; Skoetz N
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic options for adult patients with previously treated immune thrombocytopenia - a systematic review and network meta-analysis.
    Yang R; Lin L; Yao H; Ji O; Shen Q
    Hematology; 2019 Dec; 24(1):290-299. PubMed ID: 30661482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Additional efficacy analysis of avatrombopag phase III data for the treatment of adults with immune thrombocytopenia.
    Jain S; Gernsheimer T; Kolodny S; Bernheisel C; Vredenburg M; Panch SR
    Platelets; 2023 Dec; 34(1):2195016. PubMed ID: 37013676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia.
    Garnock-Jones KP
    Drugs; 2011 Jul; 71(10):1333-53. PubMed ID: 21770480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Eltrombopag for chronic immune thrombocytopenia.
    Tanimoto T; Fukunaga S; Hori A; Yagasaki F; Ono S
    Lancet; 2011 Jun; 377(9781):1919; author reply 1919-20. PubMed ID: 21641478
    [No Abstract]   [Full Text] [Related]  

  • 35. Eltrombopag for use in children with immune thrombocytopenia.
    Kim TO; Despotovic J; Lambert MP
    Blood Adv; 2018 Feb; 2(4):454-461. PubMed ID: 29487060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eltrombopag: an oral thrombopoietin receptor agonist for the treatment of idiopathic thrombocytopenic purpura.
    Zhang Y; Kolesar JM
    Clin Ther; 2011 Nov; 33(11):1560-76. PubMed ID: 22054810
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
    Atkinson K
    Clin J Oncol Nurs; 2019 Apr; 23(2):212-216. PubMed ID: 30880797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of thrombopoietin receptor agonists in children and adults with persistent and chronic immune thrombocytopenia: a meta-analysis.
    Li T; Liu Q; Pu T; Liu J; Zhang A
    Expert Opin Pharmacother; 2023 Apr; 24(6):763-774. PubMed ID: 37010022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TPO receptor agonist for chronic idiopathic thrombocytopenic purpura.
    Zeng Y; Duan X; Xu J; Ni X
    Cochrane Database Syst Rev; 2011 Jul; 2011(7):CD008235. PubMed ID: 21735426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of avatrombopag in Chinese children with persistent and chronic primary immune thrombocytopenia: A multicentre observational retrospective study in China.
    Wang Z; Zhang A; Xu Z; Wang N; Zhang J; Meng J; Dong S; Ma J; Hu Y; Ouyang J; Chen Z; An Q; Cheng X; Wu R
    Br J Haematol; 2024 May; 204(5):1958-1965. PubMed ID: 38362793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.